Shareholder Update: May 2013
In this issue:
› VivaGel® update
› New agrochemical partnership
› SPL7013 shows therapeutic potential in viral conjunctivitis
› Positive dendrimer-doxorubicin results
› Key patents obtained
› R&D tax refund received
› Momentum builds in nanomedicine
› Substantial holders increase their stake
Download: Shareholder Update: May 2013 ( pdf file, 1MB)
Starpharma Boardroom Radio Interview
Starpharma is pleased to provide investors with the opportunity to listen to an audio interview with Chief Executive Officer Dr Jackie Fairley on Boardroom Radio (BRR).
Starpharma presenting at Goldman Sachs Emerging Companies Conference
Starpharma will today present to institutional fund managers at the Goldman Sachs Emerging Companies conference in Sydney.
The invitation-only event involves 35 companies across all sectors. Starpharma is one of three healthcare companies invited to attend - the other two are Blackmores and Sigma Pharmaceuticals.
Starpharma's dendrimer a potential viral conjunctivitis treatment
Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) today announced that the Company’s clinical-stage dendrimer SPL7013 has shown potent antiviral effect against adenovirus, the agent responsible for the majority of viral conjunctivitis cases.